Sanofi Pasteur Opens New Facility in France
Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, has announced the inauguration of a high-tech vaccine production facility in France in response to soaring demand worldwide.
This new E100 million facility, located in Val de Reuil (North West of France), incorporates the latest technology to produce vaccines that meet the highest standards of quality. It is part of E600 million investments undertaken by Sanofi Pasteur in France between 2005 and 2008.
The new highly automated facility can produce vaccines against 20 diseases. It is designed to be ready to switch to pandemic influenza vaccine in the event of a human pandemic influenza, and once a pandemic influenza strain is identified by the World Health Organization.
Construction of the 7,800 square-meter building began in 2006. It is projected to be operational by the end of 2008, upon certification by health authorities. The facility is scaled to fill 200 million syringes and vials per year, increasing by two fold the current capacity at this site.
Wayne Pisano, president and CEO of Sanofi Pasteur, said: “The new facility will further enable Sanofi Pasteur to fulfill its commitment of providing highest quality vaccines to protect people from infectious diseases wherever they live.”